The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While both classes demonstrate remarkable efficacy in achieving glycemic control and facilitating significant weight management, k

In the ever-evolving landscape of diabetes management, a innovative approach is emerging that focuses on directly targeting glucose levels. This innovative strategy involves leveraging the power of two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP have shown promising results in